TGA lets Lifeblood produce faecal transplants for use outside of clinical trials
Faecal microbiota transplant will now be available to patients outside clinical trials.
Red Cross Lifeblood has received approval to produce faecal microbiota transplants for treating Clostridioides difficile outside of a clinical trial.
Hospitals can now order supplies of Lifeblood-processed faecal microbiota transplants (FMT) to administer to patients with C. difficile who do not respond to antibiotics.
Unlike blood, with its shelf life of 28 to 42 days, FMT can be stored for 12 months under the right conditions.
Lifeblood lead medical microbiologist Dr Bryant Koh said that Lifeblood aimed to provide consistency in FMT preparation.
